Side-by-side · Research reference

CartalaxvsSemaglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BFDA-ApprovedFlagship15/53 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Cartalax

Semaglutide

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Antibody development

—

02Dosage Protocols

Parameter

Cartalax

Semaglutide

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Standard dose (T2D, Ozempic)

—

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

Standard dose (weight, Wegovy)

—

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

Frequency

—

Once weekly, same day each week

Titration schedule

—

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

Duration

—

Indefinite for chronic indication

Discontinuation results in weight regain.

Reconstitution

—

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Timing

—

Any time of day, with or without food

Half-life

—

~7 days (168 h)WEGOVY (semaglutide) injection 2021

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

Semaglutide

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

Semaglutide

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

—

GI symptoms

—

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

Hypoglycemia

—

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Pregnancy / OB

—

ContraindicatedWEGOVY (semaglutide) injection 2021

Heart rate

—

Modest ↑ resting HR (~2-4 bpm)

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

05Administration Protocol

Parameter

Cartalax

Semaglutide

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Once weekly, same day. Day can be changed if ≥2 days separate doses.

4. Storage

—

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

5. Needle

—

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

06Stack Synergy

Cartalax

— no documented stacks

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)